Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 110

1.

National EQ-5D tariffs and quality-adjusted life-year estimation: comparison of UK, US and Danish utilities in south Swedish rheumatoid arthritis patients.

Karlsson JA, Nilsson JÅ, Neovius M, Kristensen LE, Gülfe A, Saxne T, Geborek P.

Ann Rheum Dis. 2011 Dec;70(12):2163-6. doi: 10.1136/ard.2011.153437. Epub 2011 Aug 22.

PMID:
21859684
2.
3.

Infliximab: a pharmacoeconomic review of its use in rheumatoid arthritis.

Lyseng-Williamson KA, Foster RH.

Pharmacoeconomics. 2004;22(2):107-32. Review.

PMID:
14731052
4.

US and UK versions of the EQ-5D preference weights: does choice of preference weights make a difference?

Huang IC, Willke RJ, Atkinson MJ, Lenderking WR, Frangakis C, Wu AW.

Qual Life Res. 2007 Aug;16(6):1065-72. Epub 2007 Apr 6.

PMID:
17415683
5.

Does the choice of EQ-5D tariff matter? A comparison of the Swedish EQ-5D-3L index score with UK, US, Germany and Denmark among type 2 diabetes patients.

Kiadaliri AA, Eliasson B, Gerdtham UG.

Health Qual Life Outcomes. 2015 Sep 15;13:145. doi: 10.1186/s12955-015-0344-z.

6.

Rapid and sustained health utility gain in anti-tumour necrosis factor-treated inflammatory arthritis: observational data during 7 years in southern Sweden.

Gülfe A, Kristensen LE, Saxne T, Jacobsson LT, Petersson IF, Geborek P.

Ann Rheum Dis. 2010 Feb;69(2):352-7. doi: 10.1136/ard.2008.103473. Epub 2009 Mar 11.

PMID:
19282310
7.

Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in early rheumatoid arthritis: 2-year quality-of-life results of the randomised, controlled, SWEFOT trial.

Karlsson JA, Neovius M, Nilsson JÅ, Petersson IF, Bratt J, van Vollenhoven RF, Ernestam S, Geborek P.

Ann Rheum Dis. 2013 Dec;72(12):1927-33. doi: 10.1136/annrheumdis-2012-202062. Epub 2012 Nov 29.

PMID:
23196701
8.

Gain in quality-adjusted life-years in patients with rheumatoid arthritis during 1 year of biological therapy: a prospective study in clinical practice.

Linde L, Sørensen J, Østergaard M, Hetland ML.

J Rheumatol. 2013 Sep;40(9):1479-86. doi: 10.3899/jrheum.121387. Epub 2013 Jul 1. Erratum in: J Rheumatol. 2013 Sep;40(9):1634. Merete, Lund Hetland [corrected to Hetland, Merete Lund].

PMID:
23818719
9.

A comparison of United States and United Kingdom EQ-5D health states valuations using a nonparametric Bayesian method.

Kharroubi SA, O'Hagan A, Brazier JE.

Stat Med. 2010 Jul 10;29(15):1622-34. doi: 10.1002/sim.3874.

PMID:
20209481
10.

Comparative responsiveness of the EuroQol-5D and Short Form 6D to improvement in patients with rheumatoid arthritis treated with tumor necrosis factor blockers: results of the Dutch Rheumatoid Arthritis Monitoring registry.

Buitinga L, Braakman-Jansen LM, Taal E, Kievit W, Visser H, van Riel PL, van de Laar MA.

Arthritis Care Res (Hoboken). 2012 Jun;64(6):826-32. doi: 10.1002/acr.21619. Epub 2012 Jan 19.

11.
12.

Choosing between measures: comparison of EQ-5D, HUI2 and HUI3 in persons with hearing complaints.

Grutters JP, Joore MA, van der Horst F, Verschuure H, Dreschler WA, Anteunis LJ.

Qual Life Res. 2007 Oct;16(8):1439-49. Epub 2007 Jul 24.

13.

Not all "quality-adjusted life years" are equal.

Marra CA, Marion SA, Guh DP, Najafzadeh M, Wolfe F, Esdaile JM, Clarke AE, Gignac MA, Anis AH.

J Clin Epidemiol. 2007 Jun;60(6):616-24. Epub 2006 Dec 22.

PMID:
17493521
14.

Modelling the cost effectiveness of TNF-alpha antagonists in the management of rheumatoid arthritis: results from the British Society for Rheumatology Biologics Registry.

Brennan A, Bansback N, Nixon R, Madan J, Harrison M, Watson K, Symmons D.

Rheumatology (Oxford). 2007 Aug;46(8):1345-54. Epub 2007 Jun 11.

15.

Rapid and sustained improvement in health-related quality of life and utility for 72 weeks in patients with ankylosing spondylitis receiving etanercept.

Boonen A, Patel V, Traina S, Chiou CF, Maetzel A, Tsuji W.

J Rheumatol. 2008 Apr;35(4):662-7. Epub 2008 Feb 15.

PMID:
18278836
16.

The clinical and cost-effectiveness of anakinra for the treatment of rheumatoid arthritis in adults: a systematic review and economic analysis.

Clark W, Jobanputra P, Barton P, Burls A.

Health Technol Assess. 2004 May;8(18):iii-iv, ix-x, 1-105. Review.

17.

Utility-based outcomes made easy: the number needed per quality-adjusted life year gained. An observational cohort study of tumor necrosis factor blockade in inflammatory arthritis from Southern Sweden.

Gülfe A, Kristensen LE, Saxne T, Jacobsson LT, Petersson IF, Geborek P.

Arthritis Care Res (Hoboken). 2010 Oct;62(10):1399-406. doi: 10.1002/acr.20235.

18.

Cost-utility analysis of treatment with olanzapine compared with other antipsychotic treatments in patients with schizophrenia in the pan-European SOHO study.

Knapp M, Windmeijer F, Brown J, Kontodimas S, Tzivelekis S, Haro JM, Ratcliffe M, Hong J, Novick D; SOHO Study Group.

Pharmacoeconomics. 2008;26(4):341-58.

PMID:
18370568
19.

Scale characteristics and mapping accuracy of the US EQ-5D, UK EQ-5D, and SF-6D in patients with rheumatoid arthritis.

Wolfe F, Michaud K, Wallenstein G.

J Rheumatol. 2010 Aug 1;37(8):1615-25. doi: 10.3899/jrheum.100043. Epub 2010 Jun 15. Erratum in: J Rheumatol. 2010 Sep;37(9):1979.

PMID:
20551106
20.

Assessing utility values in rheumatoid arthritis: a comparison between time trade-off and the EuroQol.

Ariza-Ariza R, Hernández-Cruz B, Carmona L, Dolores Ruiz-Montesinos M, Ballina J, Navarro-Sarabia F; Costs and Quality of Life in Rheumatoid Arthritis Study Group.

Arthritis Rheum. 2006 Oct 15;55(5):751-6.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk